A jury of professional investors and Medtech experts reviewed 60 applications to select this year’s Swiss National Team for Venture Leaders Medtech. The one-week business development roadshow to Boston – the world’s major life sciences hubs – gives ten selected startups the opportunity to explore the US market, meet investors and engage with executives and experts in the Medtech industry. The current cohort presents a wide array of solutions for challenges in the medical field such as increasing organ transplant availability, enhancing orthopaedic aftercare with implantable biosensors, improving fertility treatments. Some startups are leveraging AI to transform complex disease data into actionable insights for precision medicine.
Prior to the roadshow from 4.8 November, the startups will present their solutions to the audience at the Meet the Venture Leaders Medtech 2024 event. Join the team’s introduction and online pitch session on September 19th, 2024.
The selected startups are:
Apersys | Zurich – is on a mission to save more patients in need of an organ transplant. Its perfusion platform technology lays the ground for improving the number of transplantable organs and fostering translational research.
Aseptuva | Bern – aims to prevent secondary infections in hospitals using a patented Far-UVC technology. Its medical devices can safely disinfect catheter-entry sites in a targeted and hands-free manner, thereby saving thousands of patients’ lives, reducing the burden on health workers, and combatting the rise in antimicrobial resistance.
BIOS Medical | Davos – is pioneering a revolution in orthopaedic aftercare through implantable biosensors. The Medtech startup monitors progress remotely 24/7 to enable a personalized care pathway and empower the patient.
Calico BIosystems | Crissier (Vaud) – is an experimental and digital platform that reliably tests the efficacy of anti-cancer drugs on patient tumors and de-risks their clinical development by predicting life-changing drugs for cancer patients.
Citus | Dübendorf – offers evidence-based skin assessment. By objective and non-invasive measurements combined with a holistic database, Citus enables staging degrees of skin disease with a single measurement. In combination with artificial intelligence, this allows for predictive care and early detection of intervention points.
Impli | Root (Lucerne) – aims to revolutionize healthcare with its high-precision hormone monitoring platform, starting with the infertility market affecting 186 million individuals worldwide. By delivering precise hormone measurements, Impli enhances IVF treatments and supports women dealing with menopause, Polycystic ovary syndrome (PCOS), hormonal imbalances, pregnancy, and contraception.
Metadvice AI | Saint-Sulpice (Vaud) – distils complex disease treatment and outcome data into actionable insights for clinicians and patients, assisting pharmaceutical companies with real-world evidence. The clinical knowledge engine sources data from a network of practitioners to take precision medicine to the next level.
MYNERVA | Zurich – developed Leia, a groundbreaking medical device able to reduce falls and chronic pain in patients suffering from diabetic neuropathy through a combination of Artificial Intelligence and Non-invasive neurostimulation.
OncoSwab | Courroux (Jura) – seeks to transform lung cancer detection with a non-invasive nasal fluid test, enabling early diagnosis for timely, life-saving interventions. The startup’s approach promises faster results, reduced costs, and greater sensitivity compared to traditional invasive methods.
OneTwenty | Zurich – enhances diabetes management by pioneering AI-driven algorithms, delivering the first safe solution that autonomously navigates human metabolism for relief to people with diabetes. Leading global Medtech companies collaborate with OneTwenty, and additional pilot projects are underway.
(Press release/RAN)